HSIC Quote, Financials, Valuation and Earnings

Ainos has a net margin of 3.47% compared to Henry Schein's net margin of -15991.17%. Henry Schein's return on equity of 8.28% beat Ainos's return on equity of -52.95%.

Henry Schein has a consensus price target of $76.39, signalling upside risk potential of 6.02%. On the other hand Ainos has an analysts' consensus of -- which suggests that it could fall by --. Given that Henry Schein has higher upside potential than Ainos, analysts believe Henry Schein is more attractive than Ainos.

Henry Schein has a beta of 0.871, which suggesting that the stock is 12.861% less volatile than S&P 500. In comparison Ainos has a beta of 2.137, suggesting its more volatile than the S&P 500 by 113.734%.

Henry Schein has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ainos offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Henry Schein pays -- of its earnings as a dividend. Ainos pays out -- of its earnings as a dividend.

Henry Schein quarterly revenues are $3.2B, which are larger than Ainos quarterly revenues of $20.7K. Henry Schein's net income of $110M is higher than Ainos's net income of -$4.7M. Notably, Henry Schein's price-to-earnings ratio is 22.52x while Ainos's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Henry Schein is 0.72x versus 56.59x for Ainos. Usually stocks with elevated PS ratios are considered overvalued.

Intelligent Bio Solutions has a net margin of 3.47% compared to Henry Schein's net margin of -370.29%. Henry Schein's return on equity of 8.28% beat Intelligent Bio Solutions's return on equity of -164.63%.

Henry Schein has a consensus price target of $76.39, signalling upside risk potential of 6.02%. On the other hand Intelligent Bio Solutions has an analysts' consensus of -- which suggests that it could grow by 883.61%. Given that Intelligent Bio Solutions has higher upside potential than Henry Schein, analysts believe Intelligent Bio Solutions is more attractive than Henry Schein.

Henry Schein has a beta of 0.871, which suggesting that the stock is 12.861% less volatile than S&P 500. In comparison Intelligent Bio Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Henry Schein has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Henry Schein pays -- of its earnings as a dividend. Intelligent Bio Solutions pays out -- of its earnings as a dividend.

Henry Schein quarterly revenues are $3.2B, which are larger than Intelligent Bio Solutions quarterly revenues of $607.5K. Henry Schein's net income of $110M is higher than Intelligent Bio Solutions's net income of -$2.2M. Notably, Henry Schein's price-to-earnings ratio is 22.52x while Intelligent Bio Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Henry Schein is 0.72x versus 1.40x for Intelligent Bio Solutions. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools has a net margin of 3.47% compared to Henry Schein's net margin of -63.81%. Henry Schein's return on equity of 8.28% beat Standard BioTools's return on equity of -26.52%.

Henry Schein has a consensus price target of $76.39, signalling upside risk potential of 6.02%. On the other hand Standard BioTools has an analysts' consensus of $2.38 which suggests that it could grow by 119.91%. Given that Standard BioTools has higher upside potential than Henry Schein, analysts believe Standard BioTools is more attractive than Henry Schein.

Henry Schein has a beta of 0.871, which suggesting that the stock is 12.861% less volatile than S&P 500. In comparison Standard BioTools has a beta of 1.804, suggesting its more volatile than the S&P 500 by 80.443%.

Henry Schein has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Henry Schein pays -- of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend.

Henry Schein quarterly revenues are $3.2B, which are larger than Standard BioTools quarterly revenues of $40.8M. Henry Schein's net income of $110M is higher than Standard BioTools's net income of -$26M. Notably, Henry Schein's price-to-earnings ratio is 22.52x while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Henry Schein is 0.72x versus 2.38x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

LENSAR has a net margin of 3.47% compared to Henry Schein's net margin of -193.13%. Henry Schein's return on equity of 8.28% beat LENSAR's return on equity of -464.33%.

Henry Schein has a consensus price target of $76.39, signalling upside risk potential of 6.02%. On the other hand LENSAR has an analysts' consensus of $15.00 which suggests that it could grow by 6.31%. Given that LENSAR has higher upside potential than Henry Schein, analysts believe LENSAR is more attractive than Henry Schein.

Henry Schein has a beta of 0.871, which suggesting that the stock is 12.861% less volatile than S&P 500. In comparison LENSAR has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Henry Schein has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Henry Schein pays -- of its earnings as a dividend. LENSAR pays out -- of its earnings as a dividend.

Henry Schein quarterly revenues are $3.2B, which are larger than LENSAR quarterly revenues of $14.2M. Henry Schein's net income of $110M is higher than LENSAR's net income of -$27.3M. Notably, Henry Schein's price-to-earnings ratio is 22.52x while LENSAR's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Henry Schein is 0.72x versus 2.87x for LENSAR. Usually stocks with elevated PS ratios are considered overvalued.